Plain-English translation of NCT06503510 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing a medication called Lebrikizumab to understand how it affects itch and pain sensitivity in the body. The medication works by blocking a specific immune protein that scientists believe contributes to intense itching. This is the first time this particular approach is being studied in humans to learn more about the biological mechanisms of itch.
Intense itch is one of the most bothersome symptoms of atopic dermatitis and other skin conditions, but doctors don't fully understand why the itch happens or how to best treat it. This study aims to fill that gap by testing whether blocking this specific immune pathway can reduce itch sensitivity, which could lead to better treatments in the future.
You likely qualify if…
You likely don't qualify if…
You would receive three injections of the medication over four weeks: two injections at the start (week 0 and week 2), and one more at week 4. Between study visits, researchers would perform specialized tests to measure how your skin and nerves respond to itch and pain. You would need to avoid certain medications and alcohol for 24 hours before test days, and arrange time for study appointments.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Denmark